The positives so far… Relapsing-Remitting Multiple Sclerosis Drug Copaxone Gets FDA Approval For Bigger Dose, Fewer Injections BioNews Texas – Copaxone injection for relapsing-remitting multiple sclerosis There is new news regarding a widely-used treatment for Relapsing-Remitting Multiple Sclerosis. According to the latest reports released by Teva Pharmaceutical Industries, the FDA has approved the company’s concentrated 3-times-per-week formulations of Copaxone, and that the formulation will now be available in 40 mg dosages. Secondary Progressive MS Trial of Lamotrigine Tested For Neuroprotection Benefits BioNews Texas – The research team proposed that delaying nerve cell destruction can limit the rate of disability in secondary progressive MS patients. The supporting study, which was completed after two years of testing, was aimed at employing nerve cell blockers like lamotrigine to monitor the rate of worsening disability…